Navigation Links
Win a $10,000 Education Fund for Your Miracle Child
Date:4/9/2008

Ferring Pharmaceuticals Announces 2008 My Little Miracle Essay Contest

PARSIPPANY, N.J., April 9, 2008 /PRNewswire/ -- If you are a parent who has successfully given birth using Ferring Pharmaceuticals' fertility products, you can win a $10,000 education fund to support your child's future. Eleven other education fund prizes will also be awarded. To be eligible, all you need to do is write a brief essay. The topic is: If I Knew Then What I Know Now, explaining what advice you would give to other women who are just beginning their journey to parenthood and how you would describe your success using BRAVELLE(R) (urofollitropin for injection, purified) and/or MENOPUR (R) (menotropins for injection, USP) as part of your treatment plan.

Ferring's My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE(R) and/or MENOPUR(R). The contest celebrates the miracle of birth for parents who have faced infertility, and carries on Ferring's tradition of supporting patients by offering education funds for the winners' children.

Ferring is also awarding a $2,500 education fund to the runner up and $500 each to 10 honorable mention winners. Since announcing the first contest in 2004, Ferring has awarded $85,000 in education funds.

Essays should not exceed 2,000 words. They must be written in English, include the entrant's name, address, phone number and age, as well as the child(ren)'s name(s) and age(s), and be submitted with a contest application and labeled digital photo. Entries must be postmarked by August 30, 2008. Winners will be announced at the 64th Annual Meeting of the American Society for Reproductive Medicine (ASRM), November 8-12, 2008.

For more details and a contest application, visit http://www.ferringfertility.com or http://www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

BRAVELLE(R) and MENOPUR (R), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE(R) and/or MENOPUR (R) may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets BRAVELLE(R), MENOPUR(R), REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of orthopaedic and urology products includes EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in the knee. Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R)/DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit http://www.ferringusa.com or http://www.ferringfertility.com.

Please contact Christine Stroup for full prescribing information.


'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Eastern Ergonomics Conference, June 24 in New York City; New One-Day Format, Focus on Core Ergonomics Education
2. New Books on Best Practices in Biotechnology Business Development and Biotechnology Education
3. Ventria Receives Friends of Education Award From Geary County School District
4. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
5. The American Fertility Association Brings Fertility Education to San Francisco or Parent Hopefuls - Straight and Gay
6. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
7. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
8. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
9. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
10. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
11. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
Breaking Biology News(10 mins):